4.7 Article

Clinical and biochemical indexes from 2019-nCoV infected patients linked to viral loads and lung injury

Journal

SCIENCE CHINA-LIFE SCIENCES
Volume 63, Issue 3, Pages 364-374

Publisher

SCIENCE PRESS
DOI: 10.1007/s11427-020-1643-8

Keywords

2019-nCoV; Angiotensin II; ARDS

Categories

Funding

  1. National Science and Technology Major Project [2017ZX10103011, 2017ZX10204401]
  2. Chinese Academy of Medical Sciences Innovation Fund for Medical Sciences [2017-I2M-1-009]
  3. Shenzhen Science and Technology Research and Development Project [JCYJ20180504165549581, JCYJ20170413141236903]
  4. China Postdoctoral Science Foundation [2019T120147]

Ask authors/readers for more resources

The outbreak of the 2019-nCoV infection began in December 2019 in Wuhan, Hubei province, and rapidly spread to many provinces in China as well as other countries. Here we report the epidemiological, clinical, laboratory, and radiological characteristics, as well as potential biomarkers for predicting disease severity in 2019-nCoV-infected patients in Shenzhen, China. All 12 cases of the 2019-nCoV-infected patients developed pneumonia and half of them developed acute respiratory distress syndrome (ARDS). The most common laboratory abnormalities were hypoalbuminemia, lymphopenia, decreased percentage of lymphocytes (LYM) and neutrophils (NEU), elevated C-reactive protein (CRP) and lactate dehydrogenase (LDH), and decreased CD8 count. The viral load of 2019-nCoV detected from patient respiratory tracts was positively linked to lung disease severity. ALB, LYM, LYM (%), LDH, NEU (%), and CRP were highly correlated to the acute lung injury. Age, viral load, lung injury score, and blood biochemistry indexes, albumin (ALB), CRP, LDH, LYM (%), LYM, and NEU (%), may be predictors of disease severity. Moreover, the Angiotensin II level in the plasma sample from 2019-nCoV infected patients was markedly elevated and linearly associated to viral load and lung injury. Our results suggest a number of potential diagnosis biomarkers and angiotensin receptor blocker (ARB) drugs for potential repurposing treatment of 2019-nCoV infection.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available